Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia
- 4 June 2004
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 176 (3-4) , 312-319
Abstract
Rationale The rat neonatal ventral hippocampal (VH) ibotenic lesion model has been proposed as a developmental model of schizophrenia, based on evidence that it encompasses aspects of the disorder including psychomotor agitation (hyperactivity), deficits in prepulse inhibition (PPI), and deficits in social interaction (SI), measures presumed to reflect positive symptoms, sensory gating deficits and negative symptoms, respectively. However, validation of the model as a predictive pharmacological screening tool has been minimal. Objective Determine the effects of a chronic 3-week low dose treatment of clozapine or risperidone on locomotor hyperactivity, PPI and SI in lesioned and control rats. Results Both clozapine, 2.5 mg/kg per day IP and risperidone, 0.1 mg/kg per day IP, reversed lesion-induced locomotor hyperactivity; however, the compounds also decreased locomotor activity in the non-lesioned controls. Clozapine 2.5 mg/kg per day and risperidone 0.1 mg/kg per day significantly attenuated lesion-induced PPI deficits. Neither compound induced a significant attenuation of lesion-induced SI deficits. In order to see if SI deficits required a higher dose of an antipsychotic, the dose of clozapine was increased to 4 mg/kg per day; however this dose induced such marked decreases in the activity and startle responses in the control rats, i.e. up to 74% decrease, that the effects on the lesioned rats could not be adequately interpreted. Conclusions These data add further support to the neonatal VH lesion model as a predictive pharmacological screening assay for identifying compounds effective in the treatment of positive symptoms of schizophrenia. However, the usefulness of the model in detecting compounds effective in treating negative symptoms of schizophrenia is still in question.Keywords
This publication has 20 references indexed in Scilit:
- Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo OccupancyThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Disruption of Prepulse Inhibition of Startle Reflex in a Neurodevelopmental Model of Schizophrenia Reversal by Clozapine, Olanzapine and Risperidone But Not by HaloperidolNeuropsychopharmacology, 2002
- Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychoticsSchizophrenia Research, 2002
- Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- Atypical Antipsychotics: New Directions and New Challenges in the Treatment of SchizophreniaAnnual Review of Medicine, 2001
- Cognitive Effects of Neonatal Hippocampal Lesions in a Rat Model of SchizophreniaNeuropsychopharmacology, 1996
- The effect of clozapine on the course of illness in chronic schizophreniaInternational Clinical Psychopharmacology, 1996
- Time required for initial improvement during clozapine treatment of refractory schizophreniaAmerican Journal of Psychiatry, 1996
- Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphinePsychopharmacology, 1995
- Subchronic Treatment with Haloperidol and Clozapine in Rats with Neonatal Excitotoxic Hippocampal DamageNeuropsychopharmacology, 1994